Exchange: NYSE·Updated 05:41 PM EDT

JNJ News

News
all
press releases
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
Zacks
More News
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor...
Business Wire
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Zacks
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Zacks
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Zacks
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors...
Business Wire
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Zacks
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
Key PointsJ&J's portfolio primarily includes small biotech and medtech companies...
Nasdaq News: Markets
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
Stocktwits
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie continues to expand its portfolio in high-growth areas like immunology and neuroscience...
Nasdaq News: Markets

Advertisement|Remove ads.